Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer

摘要: Evaluation of the combined regimen estramustine and docetaxel (Taxotere; Rhone-Poulenc Rorer, Collegeville, PA) in men with hormone-refractory prostate cancer is its early stages. While this combination promising terms efficacy, adverse events associated are a concern. Estramustine has been side effects such as nausea, vomiting, edema, serious vascular events. Reported here results phase I II trials which 280 mg was given three times daily on days to 5 21-day treatment cycles at varying doses. Data from patients evaluable thus far support efficacy combination, both chemotherapeutically naive those who have had prior therapy. A survival benefit appears achievable these studies. As significant antitumor activity can be achieved alone, future studies need define minimal dose for combination.